About: Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19
Creator	Mitchell, Joanne Chowdary, Pratima Morrow, Gael Mutch, Nicola Whyte, Claire
Source	Medline; PMC
abstract	The global pandemic of coronavirus disease 2019 (COVID‐19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID‐19 patients show elevated D‐Dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI‐1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID‐19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre‐existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue‐type plasminogen activator (tPA), to treat COVID‐19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID‐19 patients to degrade fibrin and improving oxygenation in critically ill patients.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1111/jth.14872
bibo:pmid	32329246
has license	no-cc
sha1sum (hex)	678f3bb0c10bc8a6584b2841f7a680c29b18aa83
schema:url	https://doi.org/10.1111/jth.14872
resource representing a document's title	Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19
has PubMed Central identifier	PMC7264738
has PubMed identifier	32329246
schema:publication	J Thromb Haemost
resource representing a document's body	covid:678f3bb0c10bc8a6584b2841f7a680c29b18aa83#body_text
is schema:about of	named entity 'acute respiratory distress syndrome (ARDS)' named entity 'FIGURES' named entity 'Figures' named entity 'acute respiratory distress syndrome' named entity 'COVID' named entity 'Fibrinolytic' named entity 'Abstract' named entity 'CT scans' named entity 'non-infectious diseases' named entity 'PAI-1' named entity 'ARDS' named entity 'ARDS' named entity 'streptokinase' named entity 'Prothrombin time' named entity 'Attenuation' named entity 'nebulised' named entity 'ARDS' named entity 'case report' named entity 'alveolar' named entity 'platelet derived growth factor' named entity 'molecular mechanisms' named entity 'ARDS' named entity 'fibrin' named entity 'alveolar' named entity 'thrombin' named entity 'lungs' named entity 'proinflammatory cytokines' named entity 'ALI' named entity 'aetiology' named entity 'Coronavirus' named entity 'lung' named entity 'intravenous infusions' named entity 'tPA' named entity 'tPA' named entity 'plasminogen' named entity 'tightly regulated' named entity 'Older age' named entity 'multiorgan failure' named entity 'CTGF' named entity 'ARDS' named entity 'protein' named entity 'bronchoalveolar lavage' named entity 'thrombolytic therapy' named entity 'epidemic' named entity 'lungs' named entity 'acute respiratory distress syndrome' named entity 'anti-inflammatory' named entity 'biomarkers' named entity 'influenza' named entity 'cough' named entity 'nebulised' named entity 'mouse models' named entity 'Wuhan' named entity 'lung' named entity 'monocytes' named entity 'IL-8' named entity 'heparin' named entity 'SARS-CoV-2' named entity 'biomarker' named entity 'global pandemic' named entity 'collagen' named entity 'NETs' named entity 'PLATyPuS' named entity 'tPA' named entity 'COVID-19' named entity 'ARDS' named entity 'fibrin' named entity 'plastic bronchitis' named entity 'Fibrin' named entity 'thrombin' named entity 'ARDS' named entity 'fibrin' named entity 'DNase1' named entity 'alveolar' named entity 'capillary' named entity 'SARS-CoV' named entity 'coagulation factors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software